Named Bioactive Compounds · Compound
Psoralen (Furocoumarin)
Moderate Evidencecompound1 PubMed Study
Hermetica Superfood Encyclopedia
Psoralen is a naturally occurring furocoumarin compound that intercalates with DNA and forms crosslinks upon UV-A activation. It demonstrates clinical efficacy in treating mycosis fungoides and psoriasis through photochemotherapy (PUVA therapy).
Psoralen is a naturally occurring furocoumarin compound characterized by a fused furan and coumarin ring structure, primarily extracted from plants such as Psoralea corylifolia (babchi) and Ammi majus (bishop's weed). Production typically involves solvent-based extraction methods from seeds or fruits of these plants.
Key clinical evidence comes from the EORTC 21011 phase III RCT (PMID: 22924950) showing 71-77% response rates in mycosis fungoides patients, and a low-dose PUVA trial (PMID: 30892603) achieving 70% complete response. Additional RCTs demonstrate efficacy in vitiligo (PMID: 31651037) and psoriasis (PMC5967219), with comparative studies evaluating different formulations (PMID: 3294946).
Clinical studies typically use methoxsalen (8-methoxypsoralen) at 0.4-0.6 mg/kg ideal body weight, taken orally 2 hours before UVA exposure. Low-dose protocols have shown efficacy with reduced cumulative UVA exposure (median 55.8 J/cm² vs. 117.5 J/cm² for standard dose). Bath PUVA formulations are also used topically. Consult a healthcare provider before starting any new supplement.
Psoralen (furocoumarin) is a photosensitizing compound, not a nutrient, and thus lacks a traditional nutritional profile. It is a tricyclic aromatic compound (molecular formula C₁₁H₆O₃, MW ~186.16 g/mol) formed by the fusion of a furan ring with coumarin. Key details: • **Natural occurrence and concentrations**: Found in various plant sources — celery (Apium graveolens): ~1–25 mg/kg in stressed/diseased plants; parsnips (Pastinaca sativa): ~4–40 mg/kg, can reach up to 200 mg/kg in diseased roots; figs (Ficus carica): ~1–10 mg/kg in peel; limes (Citrus aurantifolia): ~1–30 mg/kg in peel oil; Ammi majus seeds: ~1,000–5,000 mg/kg (primary traditional/pharmaceutical source); Psoralea corylifolia (Babchi) seeds: ~5,000–15,000 mg/kg total furanocoumarins. • **Major bioactive derivatives**: Linear furanocoumarins include psoralen (parent compound), 8-methoxypsoralen (8-MOP/methoxsalen, most clinically used, typical therapeutic oral dose 0.4–0.6 mg/kg), 5-methoxypsoralen (5-MOP/bergapten), and trioxsalen (trimethylpsoralen). Angular furanocoumarins (e.g., angelicin) are also present in some sources but are less photoactive. • **Bioavailability**: Oral 8-MOP shows highly variable bioavailability (~20–60%), with peak plasma levels at 1–3 hours post-ingestion; bioavailability is significantly improved when taken with fatty food. Crystalline formulations show ~30% bioavailability vs. ~50–60% for micronized/liquid formulations. Hepatic first-pass metabolism is extensive (CYP2A6, CYP1A2). Topical application (0.1–1% solutions) results in local skin penetration with minimal systemic absorption. • **No macronutrient value**: Contains no protein, fat, carbohydrate, fiber, vitamins, or minerals. It is exclusively classified as a secondary plant metabolite/phytochemical with pharmacological (photosensitizing) activity. • **Photochemical properties**: Absorbs UVA radiation (320–400 nm, peak ~365 nm) and intercalates into DNA, forming mono- and di-adducts with pyrimidine bases upon photoactivation — this is the basis of PUVA (Psoralen + UVA) therapy. • **Phototoxicity threshold**: Dietary intake of furanocoumarins from normal food consumption is estimated at ~1–2 mg/day in Western diets; phototoxic effects generally require higher doses (~10–50 mg or more) combined with UVA exposure.
Psoralen intercalates between DNA base pairs and forms monoadducts and crosslinks when activated by UV-A radiation (320-400nm). This photochemical reaction inhibits DNA replication and cell division, particularly affecting rapidly dividing keratinocytes and T-lymphocytes. The compound also modulates immune responses by reducing inflammatory cytokine production.
Randomized controlled trials demonstrate 70-77% overall response rates for mycosis fungoides treatment with PUVA therapy, with 22-31% achieving complete clinical response. Psoriasis studies show ≥50% PASI reduction in treatment responders, with over 30 years of established clinical use. Most trials involve 8-methoxypsoralen at 0.6mg/kg doses combined with UV-A exposure. Evidence quality is strong for dermatological applications but limited for other conditions.
Common side effects include nausea, skin burning, and increased photosensitivity lasting 8-24 hours post-treatment. Psoralen increases risk of skin cancer, particularly squamous cell carcinoma, with long-term use. It interacts with photosensitizing medications including tetracyclines, thiazides, and phenothiazines. Contraindicated in pregnancy, lupus, and patients with history of melanoma or arsenic exposure.
